Xiao Z - Search Results

1

Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.

Zhang Y, Zhou H, Duan M, Gao S, He G, Jing H, Li J, Ma L, Zhu H, Chang C, Du X, Hong M, Li X, Liu Q, Wang W, Xu N, Yang H, Lu B, Yin H, Wu L, Suo S, Zhao Q, Xiao Z, Jin J. Zhang Y, et al. Among authors: xiao z. Am J Hematol. 2023 Oct;98(10):1588-1597. doi: 10.1002/ajh.27033. Epub 2023 Jul 20. Am J Hematol. 2023. PMID: 37470365 Clinical Trial.

2

[Clinical efficacies and safety of HAG regimen for patients with high-risk myelodysplastic syndromes: a multicentre study].

Liu H, He GS, Wu DP, Sun AN, Shao ZH, Qian SX, Xiao ZJ, Ma J, Wang SY, Xu XP, Liu T, Jin J, Chen ZC, Fang MY, Chen BA, Xu LP, Shen ZX, Ruan CG. Liu H, et al. Zhonghua Yi Xue Za Zhi. 2012 Mar 13;92(10):689-91. Zhonghua Yi Xue Za Zhi. 2012. PMID: 22781297 Clinical Trial. Chinese.

3

Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis.

Li B, Xu J, Li C, Gale RP, Xu Z, Qin T, Zhang Y, Huang G, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z. Li B, et al. Among authors: xiao z. Am J Hematol. 2014 Nov;89(11):1043-6. doi: 10.1002/ajh.23824. Epub 2014 Sep 2. Am J Hematol. 2014. PMID: 25132428 Free article.

4

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.

Jung CW, Shih LY, Xiao Z, Jie J, Hou HA, Du X, Wang MC, Park S, Eom KS, Oritani K, Okamoto S, Tauchi T, Kim JS, Zhou D, Saito S, Li J, Handa H, Jianyong L, Ohishi K, Hou M, Depei W, Takenaka K, Liu T, Hu Y, Amagasaki T, Ito K, Gopalakrishna P, Akashi K. Jung CW, et al. Among authors: xiao z. Leuk Lymphoma. 2015 Jul;56(7):2067-74. doi: 10.3109/10428194.2014.969260. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25315076 Clinical Trial.

5

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.

Cui Y, Tong H, Du X, Li B, Gale RP, Qin T, Liu J, Xu Z, Zhang Y, Huang G, Jin J, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z. Cui Y, et al. Among authors: xiao z. Exp Hematol Oncol. 2015 May 20;4:14. doi: 10.1186/s40164-015-0009-y. eCollection 2015. Exp Hematol Oncol. 2015. PMID: 26019984 Free PMC article.

6

Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study.

Wu D, Du X, Jin J, Xiao Z, Shen Z, Shao Z, Li X, Huang X, Liu T, Yu L, Li J, Chen B, He G, Cai Z, Liang H, Li J, Ruan C. Wu D, et al. Among authors: xiao z. Adv Ther. 2015 Nov;32(11):1140-59. doi: 10.1007/s12325-015-0263-8. Epub 2015 Nov 14. Adv Ther. 2015. PMID: 26568466 Free PMC article. Clinical Trial.

7

TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia.

Cui Y, Tong H, Du X, Li B, Gale RP, Qin T, Liu J, Xu Z, Zhang Y, Huang G, Jin J, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z. Cui Y, et al. Among authors: xiao z. Stem Cell Investig. 2016 Sep 23;3:50. doi: 10.21037/sci.2016.09.04. eCollection 2016. Stem Cell Investig. 2016. PMID: 27777939 Free PMC article.

8

Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia.

Luo H, Qin Y, Reu F, Ye S, Dai Y, Huang J, Wang F, Zhang D, Pan L, Zhu H, Wu Y, Niu T, Xiao Z, Zheng Y, Liu T. Luo H, et al. Among authors: xiao z. J Hematol Oncol. 2016 Nov 17;9(1):125. doi: 10.1186/s13045-016-0356-0. J Hematol Oncol. 2016. PMID: 27855695 Free PMC article.

9

Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study.

Du X, Lai YY, Xiao Z, Liu T, Hu Y, Sun A, Li X, Shen ZX, Jin J, Yu L, Laille E, Dong Q, Songer S, Beach CL. Du X, et al. Among authors: xiao z. Asia Pac J Clin Oncol. 2018 Jun;14(3):270-278. doi: 10.1111/ajco.12835. Epub 2017 Dec 28. Asia Pac J Clin Oncol. 2018. PMID: 29282890 Clinical Trial.

10

Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.

Shi D, Shi H, Liu X, Duan M, Zhuang J, Du X, Qin L, Hui W, Liang R, Wang M, Chen Y, Li D, Yang W, Tang G, Zhang W, Kuang X, Su W, Han Y, Chen L, Xu J, Liu Z, Huang J, Zhao C, Tong H, Hu J, Chen C, Chen X, Xiao Z, Jiang Q. Shi D, et al. Among authors: xiao z. Leuk Lymphoma. 2021 Nov;62(11):2703-2715. doi: 10.1080/10428194.2021.1933481. Epub 2021 Jun 8. Leuk Lymphoma. 2021. PMID: 34098836

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8,105 results

Search Page